BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 65.19 P/S
- 17.18 P/B
- -0.72 EPS
- -229.93% Cash ROIC
- 1.26 Cash Ratio
- 0 / 0% Dividend
- 908,491.00 Avg. Vol.
- 72.36M Shares
- 1.11B Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
American Trade Journal - Jul 30, 2015
Triangle Business Journal - Jun 17, 2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza ... - GlobeNewswire (press release)
Insider Trading Report - Jul 22, 2015
OTC Outlook - Jul 28, 2015
Morning Watch List: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Alcatel ... - Stock Transcript
Street Report - Jul 1, 2015
Top Growth Pick: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Enterprise Leader
OctaFinance.com - Jul 22, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rating Update - Investor Newswire
Motley Fool - Apr 1, 2015
Ebola Finances Coming Back in the News - 24/7 Wall St.
Insider Trading Report - Jul 20, 2015
News Buzz - BioCryst Pharmaceuticals (BCRX), Anacor Pharmaceuticals (ANAC ... - Techsonian (press release)
Money Flow Index - Jul 16, 2015
BioCryst Pharmaceuticals Short Interest Down 19.9% in June (BCRX) - Mideast Time
Money Flow Index - Jul 14, 2015
BioCryst Pharmaceuticals Lowered to Sell at Zacks (BCRX) - Dakota Financial News